★ Analysts see FY2028 revenue reaching $927.8B — +4.0% growth in a single year.
What Could Go Wrong
01Rising raw material costs have led to margin compression in the last quarter, with a projected 5% decline in gross margin if prices continue to rise.
02Increased competition from emerging markets is expected to pressure pricing in the healthcare segment, potentially leading to a 10% decline in revenue growth.
03Technological disruption from new materials or manufacturing processes
"Management noted, 'We are facing significant headwinds from rising input costs that could impact our profitability in the near term.'"
Moat: Teijin's competitive advantage lies in its proprietary technology and established relationships in high-performance sectors…
Watch: The rise of alternative materials and low-cost production in emerging markets poses a significant threat to Teijin's market position.
value - Teijin's low valuation metrics and potential for turnaround appeal to value investors.
Rising interest rates can increase financing costs for Teijin, impacting capital expenditures and potentially reducing demand for its…
Watch on earnings: Industrial Production Index (INDPRO), Brent crude oil price (DCOILBRENTEU), Consumer Sentiment (UMCSENT).
One Sentence Summary:
The bear case: rising raw material costs have led to margin compression in the last quarter, with a projected 5% decline in gross margin if prices continue to rise.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
